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Sulfonamide drugs are associated with a wide range of biolog-
ical activities and in fact brought an antibiotic revolution in
medicine (Ali et al., 2006; McCarroll et al., 2007; Wilkinson
et al., 2007). Many oxazole and/or thiazole containing macro-
cycles are naturally occurring molecules, viz., Bistratamides
(You and Kelly, 2005), Didmolamides A and B (You and
Kelly, 2005), Lyngbyabellin A (Yokokawa et al., 2001), and
Calyculins (Yokokawa et al., 2001; Degnan et al., 1989; Pihko
and Koskinen, 1998; Perez and Faulkner, 2003; Rudi et al.,
2003; Tan et al., 2003), which show cytotoxic, antimicrobial
and multiple drug resistance activities. Several classes of drugs
based on imidazole viz., 2-nitroimidazole commonly called
Azomycin are a natural antibiotic. Some synthetic nitroimi-
dazoles are active against intestinal infections (Breccia et al.,
1986). In fact metronidazole is used for intestinal infections
and also as a radiosensitizer in X-ray therapy (Middlemiss
and Watson, 1994). The incorporation of sulfonamide moiety
into heterocyclic rings can produce pharmacologically potent
compounds. The present work comprises design and synthesis
of new molecules having two pharmacophoric heterocyclic
units linked by bis methane amido sulfonamido moiety which
are expected to have pharmacological activity. Although
chemically unrelated to these compounds, other classes of anti-
biotics such as the anthracyclines (Miller and Stoodley, 2011)
which were originally isolated from strains of Streptomyces
peucetius, show antibacterial activity (mostly against Gram po-
sitive bacteria, for example Staphylococcus aureus) and have
been in clinical use for the treatment of various forms of cancerfor several decades. Triazolopyrazole thiones also exhibit anti-
bacterial, antifungal and promising anticancer activities; the
latter compared with the anthracycline doxorubicin.
2. Experimental
2.1. General
Melting points were determined in open capillaries on a
Mel-Temp apparatus and are uncorrected. The purity of the
compounds was checked by TLC (silica gel H, BDH, ethyl ace-
tate/hexane, 1:3). The IR spectra were recorded on a Thermo
Nicolet IR 200 FT-IR spectrometer as KBr pellets and the
wavenumbers were given in cm1. The 1H NMR spectra were
recorded in DMSO-d6 on a Bruker spectrospin operating at
400 MHz. The 13C NMR spectra were recorded in DMSO-d6
on Bruker spectrospin operating at 100 MHz. All chemical
shifts are reported in d (ppm) using TMS as an internal stan-
dard. The microanalyses were performed on a Perkin-Elmer
240C elemental analyzer. For anticancer activity the optical
density was determined at 450 nm using a microplate reader
(BioTek Instruments Inc., Winooski, VT, USA).
2.2. Synthesis of bis(carbethoxymethylsulfonyl)amine (2)
To a solution of ethyl sulfamylacetate (1) (0.003 mol) in
dichloromethane (10 ml), triethylamine (0.0031 mol), and 4-
dimethylaminopyridine (DMAP) (0.0001 mol) were added
and stirred at room temperature for 15 min. Then, a solution
of ethyl 2-chlorosulfonylacetate (0.0033 mol) in dichlorometh-
Synthesis, antimicrobial and anticancer activities of amido sulfonamido methane linked bis heterocycles 387ane (5 ml) was added dropwise and the reaction mixture was
stirred at 40 C under nitrogen atmosphere for 6–10 h. After
completion of reaction the solvent was removed in vacuo.
The resultant residue was neutralized with saturated NaHCO3
solution and the aqueous layer was extracted with ethyl acetate
(3 · 15 ml), washed with water (3 · 20 ml), and dried over
anhydrous Na2SO4. The solvent was removed under vacuum
and the residual solid was puriﬁed by column chromatography
(silica gel, 60–120 mesh) using hexane-ethyl acetate (3:1) as
eluent.
Yield 72%, m.p. 132–134 C. IR (KBr): t= 3370 (NH),
1730 (C‚O), 1320, 1136 (SO2) cm
1. 1H NMR (400 MHz,
DMSO-d6, 25 C, TMS): d= 1.36 (t, 6H, CH3), 4.20 (q, 4H,
OCH2), 4.42 (s, 4H, CH2), 8.01 (bs, 1H, NH) ppm;
13C
NMR (100 MHz, DMSO-d6, 25 C, TMS) d= 14.2 (CH3),
55.8 (CH2), 61.4 (OCH2), 161.5 (C‚O) ppm. Anal. For
C8H15NO8S2 (317.35) cacld. C30.27, H4.76, N 4.41. Found
C30.32, H4.74, N4.47.
2.3. Synthesis of bis(carboxymethylsulfonyl)amine (3)
A mixture of bis(carbethoxymethylsulfonyl)amine (2)
(0.0025 mol), KOH (0.01 mol) in methanol (10 ml) and water
(25 ml) was reﬂuxed for 2–3 h. To this charcoal was added,
boiled for 5 min. and ﬁltered through celite. The ﬁltrate was
acidiﬁed with dil. HCl and extracted with ether. Removal of
the solvent on a rotary evaporator resulted in compound 3.
Yield 80%, m.p. 145–147 C. IR (KBr): t= 3372 (NH),
3355 (OH), 1716 (C‚O), 1323, 1141 (SO2) cm
1. 1H NMR
(400 MHz, DMSO-d6, 25 C, TMS): d= 4.54 (s, 4H, CH2),
7.96 (bs, 1H, NH), 10.43 (bs, 2H, OH) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS) d= 57.6 (CH2), 174.2
(C‚O) ppm. Anal. calcd For C4H7NO8S2 (261.24) calcd.
C18.39, H2.70, N5.36. Found: C18.46, H2.71, N5.44.
2.4. General procedure for the synthesis of bis(N-(4-aryloxazol-
2-yl)aminocarbonyl–methylsulfonyl)amine (7a–c)/bis(N-(4-
arylthiazol-2-yl)aminocarbonyl–methylsulfonyl)amine (8a–c)/
bis(N-(4-aryl-1H-imidazol-2-yl)aminocarbonyl–
methylsulfonyl)amine (9a–c)
To a solution of compound 3 (0.001 mol) in dioxane (20 ml),
compound 4/5/6 (0.002 mol) and 4-dimethylaminopyridine
(DMAP) (0.0001 mol) were added. Then dicyclohexylcarbodi-
imide (DCC) (0.0014 mol) in dioxane (10 ml) was added drop-
wise to the contents while stirring at room temperature and
continued the stirring for another 20–24 h. The separated pre-
cipitate, a dicyclohexylurea was removed by ﬁltration. The
solution was evaporated to dryness and the residual solid
was puriﬁed by column chromatography (silica gel, 60–120
mesh) using hexane-ethyl acetate (3:1) as eluent.
2.4.1. Bis(N-(4-phenyloxazol-2-yl)
aminocarbonylmethylsulfonyl)amine (7a)
Yield 65%, m.p. 186–187 C. IR (KBr): t= 3344 (NH), 1690
(C‚O), 1634 (C‚C), 1574 (C‚N), 1326, 1138 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.52 (s,
4H, CH2), 7.44–7.88 (m, 12H, Ar-H and C5-H), 8.03 (bs,
1H, SO2NH), 8.46 (bs, 2H, CO-NH) ppm;
13C NMR
(100 MHz, DMSO-d6, 25 C, TMS) d= 56.2 (CH2), 128.9,129.1, 130.0, 132.6 (Ar-C), 138.2 (C-5), 140.3 (C-4), 149.7
(C-2), 167.2 (C‚O) ppm. Anal calcd For C22H19N5O8S2
(545.55) calcd. C48.43, H3.51, N12.83. Found: C48.39,
H3.54, N12.93.
2.4.2. Bis(N-(4-p-tolyloxazol-2-yl)
aminocarbonylmethylsulfonyl)amine (7b)
Yield 67%, m.p. 172–174 C. IR (KBr): t= 3338 (NH), 1683
(C‚O), 1630 (C‚C), 1580 (C‚N), 1324, 1135 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 2.40 (s,
6H, Ar-CH3), 4.48 (s, 4H, CH2), 7.15-7.48 (m, 10H, Ar-H
and C5-H), 8.05 (bs, 1H, SO2NH), 8.43 (bs, 2H, CO-NH)
ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS)
d= 24.8 (Ar-CH3), 56.0 (CH2), 127.3, 129.4, 131.0, 137.2
(Ar-C), 137.8 (C-5), 139.5 (C-4), 148.4 (C-2), 167.2 (C‚O)
ppm. Anal. For C24H23N5O8S2 (573.60) calcd. C50.25, H,
4.04, N12.20. Found: C50.30, H4.03, N12.29.
2.4.3. Bis(N-(4-p-chlorophenyloxazol-2-yl)
aminocarbonylmethylsulfonyl)amine (7c)
Yield 70%, mp 201–202 C. IR (KBr): t= 3350 (NH), 1694
(C‚O), 1627 (C‚C), 1568 (C‚N), 1332, 1145 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.45 (s, 4H,
CH2), 7.37–7.66 (m, 10H, Ar-H and C5-H), 7.98 (bs, 1H,
SO2NH), 8.48 (bs, 2H, CO-NH) ppm;
13C NMR (100 MHz,
DMSO-d6, 25 C, TMS) d= 56.5 (CH2), 127.5, 129.1, 132.4,
135.8 (Ar-C), 138.5 (C-5), 140.8 (C-4), 150.2 (C-2), 167.9
(C‚O) ppm. Anal. For C22H17Cl2N5O8S2 (614.44) calcd.
C43.00, H2.78, N11.40. Found: C43.07, H2.80, N11.48.
2.4.4. Bis(N-(4-phenylthiazol-2-yl)
aminocarbonylmethylsulfonyl)amine (8a)
Yield 72%, m.p. 190–192 C. IR (KBr): t= 3355 (NH), 1685
(C‚O), 1632 (C‚C), 1570 (C‚N), 1322, 1140 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.45
(s, 4H, CH2), 7.20–7.56 (m, 12H, Ar-H and C5-H), 7.94 (bs,
1H, SO2NH), 8.42 (bs, 2H, CO-NH) ppm;
13C NMR
(100 MHz, DMSO-d6, 25 C, TMS) d= 55.9 (CH2), 103.7
(C-5), 126.7, 127.6, 128.8, 132.0 (Ar-C), 148.0 (C-4), 162.8
(C-2), 167.4 (C‚O) ppm. Anal. For C22H19N5O6S4 (577.68)
calcd. C45.74, H3.31, N12.12. Found: C45.79, H3.30, N12.03.
2.4.5. Bis(N-(4-p-tolylthiazol-2-yl)
aminocarbonylmethylsulfonyl)amine (8b)
Yield 69%, m.p. 183–185 C. IR (KBr): t= 3348 (NH), 1673
(C‚O), 1641 (C‚C), 1565 (C‚N), 1326, 1137 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 2.38 (s,
6H, Ar-CH3), 4.43 (s, 4H, CH2), 7.10-7.43 (m, 10H, Ar-H
and C5-H), 8.01 (bs, 1H, SO2NH), 8.39 (bs, 2H, CO-NH)
ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS)
d= 24.5 (Ar-CH3), 55.3 (CH2), 103.0 (C-5), 127.9, 129.5,
130.6, 136.8 (Ar-C), 147.7 (C-4), 162.1 (C-2), 166.6 (C‚O)
ppm. Anal. For C24H23N5O6S4 (605.73) calcd. C47.58,
H3.82, N11.56. Found: C47.54, H3.85, N11.66.
2.4.6. Bis(N-(4-p-chlorophenylthiazol-2-yl)
aminocarbonylmethylsulfonyl)amine (8c)
Yield 75%, m.p. 215–217 C. IR (KBr): t= 3368 (NH), 1687
(C‚O), 1631 (C‚C), 1575 (C‚N), 1328, 1143 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.38 (s,
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388 C. Premakumari et al.4H, CH2), 7.26-7.60 (m, 10H, Ar-H and C5-H), 8.02 (bs, 1H,
SO2NH), 8.50 (bs, 2H, CO-NH) ppm;
13C NMR (100 MHz,
DMSO-d6, 25 C, TMS) d= 56.2 (CH2), 104.2 (C-5), 127.8,
129.0, 131.4, 135.0 (Ar-C), 148.4 (C-4), 163.2 (C-2), 167.8
(C‚O), Anal. For C22H17Cl2N5O6S4 (646.57) calcd. C40.86,
H2.65, N10.83. Found: C40.90, H2.63, N10.90.
2.4.7. Bis(N-(4-phenyl-1H-imidazol-2-yl)
aminocarbonylmethylsulfonyl)amine (9a)
Yield 77%, m.p. 224–226 C. IR (KBr): t= 3372 (NH), 1665
(C‚O), 1643 (C‚C), 1560 (C‚N), 1330, 1140 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.40 (s,
4H, CH2), 7.15–7.50 (m, 12H, Ar-H and C5-H), 8.04 (bs,
1H, SO2NH), 8.38 (bs, 2H, CO-NH), 11.35 (bs, 2H, NH)
ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS)
d= 55.0 (CH2), 120.3 (C-5), 127.4, 128.2, 129.7, 132.0 (Ar-
C), 137.5 (C-2), 140.0 (C-4), 166.4 (C‚O) ppm. Anal. For
C22H21N7O6S2 (543.59) calcd. C48.61, H3.89, N18.03. Found:
C48.68, H3.90, N18.14.
2.4.8. Bis(N-(4-p-tolyl-1H-imidazol-2-yl)
aminocarbonylmethylsulfonyl)amine (9b)
Yield 74%, m.p. 198–200 C. IR (KBr): t= 3370 (NH), 1660
(C‚O), 1638 (C‚C), 1550 (C‚N), 1325, 1130 (SO2) cm
1.
1H NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 2.36 (s,
6H, Ar-CH3), 4.38 (s, 4H, CH2), 7.09–7.40 (m, 10H, Ar-H
and C5-H), 7.96 (bs, 1H, SO2NH), 8.35 (bs, 2H, CO-NH),
11.28 (bs, 2H, NH) ppm; 13C NMR (100 MHz, DMSO-d6,
25 C, TMS) d= 24.7 (Ar-CH3), 54.7 (CH2), 120.1 (C-5),
127.7, 129.6, 130.8, 135.4 (Ar-C), 137.1 (C-2), 139.7 (C-4),
166.0 (C‚O) ppm. Anal. For C24H25N7O6S2 (571.64) calcd.
C50.42, H4.40, N17.15. Found: C50.49, H4.44, N17.24.
2.4.9. Bis(N-(4-p-chlorophenyl-1H-imidazol-2-yl)
aminocarbonylmethylsulfonyl)amine (9c)
Yield 78%, m.p. 243–245 C. IR (KBr): t= 3375 (NH), 1673
(C‚O), 1640 (C‚C), 1562 (C‚N), 1335, 1144 (SO2).
1H
NMR (400 MHz, DMSO-d6, 25 C, TMS) d= 4.42 (s, 4H,
CH2), 7.20-7.55 (m, 10H, Ar-H and C5-H), 7.99 (bs, 1H,
SO2NH), 8.40 (bs, 2H, CO-NH), 11.40 (bs, 2H, NH) ppm;
13C NMR (100 MHz, DMSO-d6, 25 C, TMS) d= 55.8
(CH2), 120.7 (C-5), 128.9, 130.1, 130.9, 135.5 (Ar-C), 137.9(C-2), 140.4 (C-4), 166.8 (C‚O) ppm. Anal. For
C22H19Cl2N7O6S2 (612.48) calcd. C43.14, H3.12, N16.00.
Found: C43.20, H3.11, N16.08.
2.5. Antimicrobial activity
The compounds 3–9 were evaluated for antimicrobial activity
by the agar well diffusion method and broth dilution methods.
2.5.1. Microbial cultures
Bacterial strains S. aureus, Bacillus subtilis, Pseudomonas aeru-
ginosa, Klebsiella pneumoniae and fungi Aspergillus niger and
Penicillium chrysogenum were obtained from the Department
of Microbiology, S.V University, Tirupati, India.
2.5.2. Antibacterial and antifungal assays
The in vitro antimicrobial studies were carried out by the agar
well diffusion method against test organisms (Chung et al.,
1990; Azoro, 2002). Nutrient broth (NB) plates were swabbed
with 24 h old broth culture (100 ll) of test bacteria. Using the
sterile cork borer, wells (6 mm) were made into each petriplate.
The compounds were dissolved in DMSO of 5 mg/ml and from
this 10 and 20 lL (50, 100 lg/well) were added into the wells
by using sterile pipettes. The standard antibiotics, Chloram-
phenicol, for antibacterial activity and Ketoconazole, for anti-
fungal activity (as positive control) were simultaneously tested
against the pathogens. The samples were dissolved in DMSO
which showed no zone of inhibition acts as a negative control.
The plates were incubated at 37 C for 24 h for bacteria and at
28 C for 48 h for fungi. After appropriate incubation, the
diameter of zone of inhibition of each well was measured.
Duplicates were maintained and the average values were calcu-
lated for eventual antibacterial activity.
2.5.3. Minimum inhibitory concentration assay
Broth dilution test was used to determine Minimum Inhibitory
Concentration (MIC) of the above mentioned samples
(Janovska et al., 2003; Bishnu et al., 2009). Freshly prepared
nutrient broth was used as diluents. The 24 h old culture of
the test bacteria S. aureus, B. subtilis, P. aeruginosa, K.
pneumoniae and the test fungi A. niger and P. chrysogenum
were diluted 100 fold in nutrient broth (100 ll bacterial
Table 1 The in-vitro antibacterial activity of compounds 3–9 by agar well diffusion method.
Compound Concentration (lg/Well) Zone of inhibition (mm)
Gram-positive bacteria Gram-negative bacteria
S. aureus B. subtilis P. aeruginosa K. pneumoniae
3 50 18 20 17 16
100 21 22 21 19
4a 50 – – – –
100 – – 10 –
4b 50 – – – –
100 – – – –
4c 50 – – 9 –
100 – – 12 10
5a 50 8 – 9 9
100 10 9 12 –
5b 50 – – 8 –
100 – – 10
5c 50 10 8 12 10
100 13 11 16 12
6a 50 14 13 12 10
100 17 15 16 13
6b 50 9 8 9 8
100 11 12 11 10
6c 50 19 20 17 15
100 21 23 19 18
7a 50 – – 12 10
100 – – 15 12
7b 50 – – – –
100 – – 10 10
7c 50 10 12 14 13
100 13 14 15 15
8a 50 16 15 15 12
100 18 18 19 16
8b 50 13 12 14 13
100 15 15 17 16
8c 50 17 16 17 15
100 19 17 20 18
9a 50 22 23 20 20
100 24 28 24 22
9b 50 20 19 18 17
100 23 20 22 20
9c 50 25 34 28 36
100 30 37 32 38
Chloramphenicol 50 33 34 27 40
100 35 38 30 42
Control (DMSO) – – – –
(–) No activity.
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compounds was prepared in dimethyl sulfoxide (DMSO) by
dissolving 5 mg of the compound in 1 ml of DMSO. Increasing
concentrations of the test samples (1.25, 2.5, 5, 10, 20, and
40 ll of stock solution contains 6.25, 12.5, 25, 50, 100, and
200 lg of the compounds) were added to the test tubes con-
taining the bacterial and fungal cultures. All the tubes were
incubated at 37 C for 24 h for bacteria and at 28 C for
48 h for fungi. The tubes were examined for visible turbidity
and using NB as control. Control without test samples and
with solvent was assayed simultaneously. The lowest concen-
tration that inhibited visible growth of the tested organisms
was recorded as MIC.2.5.4. Minimum bactericidal/fungicidal concentration
To determine the minimum bactericidal concentration (MBC)
(NCCLS publication M7-A3; Villanova, PA, 1993) and Mini-
mum Fungicidal Concentration (MFC) (NCCLS Document
M27-P; Villanova, PA, 1992) for each set of test tubes in the
MIC determination, a loopful of broth was collected from
those tubes which did not show any growth and inoculated
on sterile nutrient broth (for bacteria) and PDA (for fungi)
by streaking. Plates inoculated with bacteria and fungi were
incubated at 37 C for 24 h and at 28 C for 48 h, respectively.
After incubation, the lowest concentration was noted as MBC
(for bacteria) or MFC (for fungi) at which no visible growth
was observed.
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Figure 1 Antibacterial activity of 7–9.
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2.6.1. Compounds
The compounds 7c, 8c, 9a, 9b, and 9c were screened for anti-
cancer activity against NCI-H1299 (Human non-small lung
cancer cells; ATCC, Manassas, VA, USA), HCT-166 p53
(Human colorectal adenocarcinoma; ATCC, Manassas, VA,
USA), and PC-3 (Human prostate cancer cells; ATCC, Manas-
sas, VA, USA) cells by EZ-cytox cell viability assay kit.
2.6.2. Cell cultures
NCI-H1299 (Human non-small lung cancer cells; ATCC,
Manassas, VA, USA), and HCT-166 p53 (Human colorectal
adenocarcinoma; ATCC, Manassas, VA, USA), cells were cul-
tured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) (Sig-
ma-Aldrich, St. Louis, MO, USA) and PC-3 (Human prostate
cancer cells; ATCC, Manassas, VA, USA) cells were cultured
in Roswell Park Memorial Institute Medium-1640 (RPMI-
1640) (Sigma–Aldrich, St. Louis,MO,USA) supplementedwith
10% fetal bovine serum (FBS), penicillin 100 U/ml, streptomy-
cin 100 lg/ml, N-(2-hydroxyethyl)-piperazine-N0-2-ethanesul-
fonic acid (HEPES) 8 mM, and l-glutamine 2 mM. Cells were
maintained at 37 C in a humidiﬁed 5% CO2 incubator.
2.6.3. Measurement of cancer cell viability
Cell viability and proliferation were determined with EZ-cytox
cell viability assay kit (Daeil Labservice, Korea) based on the
cleavage of the tetrazolium salt to water-soluble formazan by
succinate-tetrazolium reductase system, which belongs to the
respiratory chain of the mitochondria and is active only in
the viable cells. Therefore the amount of formazan dye in-
creased with an increase in cell viability (Kwon et al., 2010).
Initially, the cells were seeded into 96-well culture plates at
1 · 104 cells/ml and NCI-H1299 and HCT-166 p53 cells were
cultured in DMEM and PC-3 cells were cultured in RPMI-1640 media containing 10% FBS at 37 C. When cells reached
70% conﬂuence, the medium was replaced with DMEM or
RPMI-1640 containing 10% FBS and each 100 lM of
compounds for 24 h. EZ-cytox cell viability kit reagents were
added to the medium, and the cells were incubated for 1 h.
The index of cell viability was determined by measuring forma-
zan production with a microplate reader at an absorbance of
450 nm. The % cell viability was calculated by the formula:
% Cell viability ¼ Mean absorbance in test wells
Mean absorbance in control wells
 100
As the % cell viability decreases the % inhibition increases.
The % inhibition was calculated by the formula:
% Inhibition ¼ 100% cell viability:
More the value of % inhibition more potent the drug is.
Cells in fresh medium without any test compound were used
as the control.
2.6.4. Statistical analysis
Experimental results are expressed as mean ± S.E.M. One-
way ANOVA followed by Dunnett’s test was used for multiple
comparisons. P values of <0.01 represent statistically signiﬁ-
cant differences.3. Results and discussion
3.1. Chemistry
The compound ethyl sulfamylacetate (1) was obtained by the
reaction of ethyl 2-chlorosulfonylacetate with ammonia
solution (Hinman and Locatell, 1959). The compound
bis(carbethoxymethylsulfonyl)amine (2) was prepared from
Table 2 The in-vitro antifungal activity of compounds 3–9 by agar well diffusion method.
Compound Concentration (lg/Well) Zone of inhibition (mm)
A. niger P. chrysogenum
3 50 25 24
100 28 28
4a 50 – –
100 – –
4b 50 – –
100 – 12
4c 50 10 13
100 13 15
5a 50 14 16
100 17 18
5b 50 12 13
100 16 16
5c 50 18 20
100 22 23
6a 50 22 23
100 25 27
6b 50 18 20
100 21 24
6c 50 25 27
100 29 31
7a 50 – –
100 – –
7b 50 – –
100 – –
7c 50 10 14
100 12 17
8a 50 20 23
100 24 26
8b 50 19 21
100 22 24
8c 50 24 24
100 26 28
9a 50 27 29
100 30 34
9b 50 22 24
100 25 26
9c 50 32 36
100 36 39
Ketoconazole 50 33 36
100 36 38
Control (DMSO) – –
(–) No activity.
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amounts of 4-dimethylaminopyridine (DMAP) and triethyl-
amine (Scheme 1). The 1HNMR spectrum of 2 displayed a trip-
let and a quartet at d 1.36 and 4.20 for ethoxy protons, a singlet
at 4.42 for methylene protons and a broad singlet at 8.01 ppm
for NH. The compound 2 on hydrolysis gave bis(carbo-
xymethylsulfonyl)amine (3). The absence of signals due to the
ethoxy group in the 1H NMR spectrum of 3 indicated that
hydrolysis occurred. Besides, a broad singlet was observed at d
10.43 ppm due to hydroxy protons in addition to signals of
the methylene and NH protons. The signals due to highly acidic
protons in 2 and 3 disappeared on deuteration. The compounds
4-aryloxazol-2-amine (4) and 4-arylthiazol-2-amine (5) were
prepared by adopting the literature precedent from phenacyl
bromide and urea/thiourea (Potewar et al., 2008). The com-
pound 4-aryl-1H-imidazole-2-amine (6) was obtained by thereaction of phenacyl bromide with acetyl guanidine followed
by hydrolysis under acidic conditions (Little and Webber,
1994). The coupling reaction of 3 with 4 in the presence of
DCC and DMAP resulted in bis(N-(4-aryloxazol-2-yl)amin-
ocarbonylmethylsulfonyl)amine (7). Similarly, the compounds
bis(N-(4-arylthiazol-2-yl)aminocarbonylmethylsulfonyl)amine
(8) and bis(N-(4-aryl-1H-imidazol-2-yl)aminocarbonylmethyl-
sulfonyl)amine (9) were synthesized by the reaction of 3 with 5
and 6 (Scheme 1). The 1H NMR spectra of 7a, 8a and 9a exhib-
ited a singlet at d 4.52, 4.45 and 4.40 for methylene protons, two
broad singlets at d 8.03, 7.94, 8.04 and 8.46, 8.42, and 8.38 for
SO2NH and CONH, respectively. However, a singlet due to
C5-H appeared in a more downﬁeld region, merged with aro-
matic protons at 7.53, 7.50 and 7.45 ppm. The structures of all
the compounds were further ascertained by IR, 13C NMR spec-
tra and microanalyses.
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Figure 2 Antifungal activity of 7–9.
Table 3 MIC, MBC and MFC of compounds 9a and 9c in broth dilution method.
Compound Minimum inhibitory concentration MIC (MBC/MFC) lg
S. aureus B. subtilis P. aeruginosa K. pneumoniae A. niger P. chrysogenum
9a 50 (200) 25 (100) 25 (100) 100 (>200) 50 (200) 100 (>200)
9c 25 (100) 6.25 (12.5) 6.25 (12.5) 50 (200) 6.25 (12.5) 12.5 (25.0)
Chloramphenicol 6.25 6.25 6.25 12.5 – –
Ketoconazole – – – – 6.25 12.5
S, Staphylococcus; B, Bacillus; P, Pseudomonas; K, Klebsiella; A, Aspergillus; P, Penicillium.
392 C. Premakumari et al.3.2. In-vitro antimicrobial activity
The compounds 3–9 were tested for antimicrobial activity by
agar well diffusion and broth dilution methods. The results
of antibacterial activity shown in Table 1 revealed that
Gram-negative bacteria were more susceptible toward the
tested compounds than Gram-positive bacteria (Fig. 1). The
compound 3 exhibited moderate antibacterial activity. Among
4, 5 and 6, compound 6c showed good antibacterial activity
against Gram-negative bacteria. However, the compounds
having amido-sulfonamido linkage 7–9 displayed greater activ-
ity when compared with the synthetic intermediates 3–6. The
compound 9c exhibited pronounced activity particularly
against B. subtilis and P. aeruginosa at 50 and 100 lg/mL when
compared with the standard drug Chloramphenicol. The bis
heterocycles having thiazole moiety (8) showed moderate
activity against the tested bacteria. On the other hand, com-
pounds with bisoxazole unit (7) exhibited least activity. The
presence of the chloro substituent on the aromatic ring en-
hanced the activity. All the tested compounds inhibited the
spore germination against tested fungi except the compounds
4 and 7. It was observed that the amido-sulfonamido linked
bis-heterocycles 7–9 showed greater antifungal activity thanthe compounds 3–6. In fact, compound 9c displayed higher
activity than the standard drug Ketoconazole against both
fungi (Table 2). All the compounds displayed slightly higher
antifungal activity toward P. chrysogenum than A. niger
(Fig. 2).
The MIC, MBC and MFC values of the compounds tested
are listed in Table 3. The compound 9c exhibited low MIC val-
ues when compared with 9a. The MBC value of compound 9c
is 2·MIC in case of B. subtilis and P. aeruginosa and MFC va-
lue is 2· MIC in case of A. niger and P. chrysogenum. How-
ever, 9a showed bactericidal and fungicidal effects greater
than 2·MIC. The structure-antimicrobial activity relationship
of the tested compounds indicated that the amido-sulfonamido
methane linked bisimidazoles are more active than bisthiazoles
and bisoxazoles. The chloro substituted bisimidazole showed
strong antibacterial activity against B. subtilis and P. aerugin-
osa and also strong antifungal activity against A. niger and P.
chrysogenum.
3.3. In-vitro anticancer activity
The amido-sulfonamido methane linked bis heterocycles 7, 8
and 9 were screened against lung (NCI-H1299), colon
Figure 3 Effects of amido sulfonamido methane linked bis heterocycles on cancer cell lines. Cells were seeded in 96-well culture plates at
1 · 104 cells/ml NCI-H1299 and HCT-166 p53 cells were cultured in DMEM and PC-3 cells were cultured in RPMI-1640 media containing
10% FBS at 37 C. When cells reached 70% conﬂuence, the medium was replaced with DMEM or RPMI-1640 containing 10% FBS and
100 lM of amido sulfonamido methane linked bis heterocycles (7c, 8c, 9a, 9b and 9c) for 23 h. Values represent means ± S.E.M. from
three different assays. (A) NCI-H1299, (B) HCT-166 p53, and (C) PC-3 cancer cell line. **p< 0.01 compared with control.
Table 4 Anticancer activity of 7c, 8c, 9a, 9b and 9c on NCI-H1299, HCT-166 p53 and PC-3 cell lines at 100 lM concentration. Cell
viability in %.
Compound NCI-H1299 HCT-166 p53 PC-3
% Viability (% inhibition) SD % Viability (% inhibition) SD % Viability (% inhibition) SD
Control 100.00 (0) ±1.76 100.00 (0) ±2.01 100.00 (0) ±1.34
7c 70.93 (29.07) ±4.08 101.50 (1.5) ±2.43 90.68 (9.32) ±4.76
8c 85.68 (14.32) ±3.40 100.80 (0.8) ±3.10 95.21 (4.79) ±1.39
9a 97.45 (2.55) ±2.67 102.52 (2.52) ±2.07 100.53 (0.53) ±4.29
9b 86.24 (13.76) ±2.47 96.69 (3.31) ±5.64 90.95 (9.05) ±1.15
9c 21.40 (78.60) ±2.25 41.38 (58.62) ±1.78 32.09 (67.91) ±4.23
Table 5 Anticancer activity of 9c on NCI-H1299, HCT-166 p53 and PC-3 cell lines at 0, 10, 50, and 100 lM concentrations. Cell
viability in %.
Compound 9c (lM) NCI-H1299 HCT-166 p53 PC-3
% Viability (% inhibition) SD % Viability (% inhibition) SD % Viability (% inhibition) SD
0 100.00 (0) ±3.10 100.00 (0) ±3.10 100.00 (0) ±3.10
10 98.26 (1.74) ±3.08 102.67 (2.67) ±8.11 54.90 (45.10) ±3.00
50 19.99 (80.01) ±8.33 89.12 (10.88) ±1.43 39.38 (60.62) ±1.28
100 19.28 (80.72) ±3.60 44.00 (56.00) ±0.34 36.61 (63.39) ±3.40
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Figure 4 The effect of compound 9c on NCI-H1299, HCT-166 p53 and PC-3 cancer cell lines: precultured, treated with compound 9c (0–
100 lM) for 23 h, EZ-cytox cell viability kit reagents were added to the medium and the cells were incubated for 1 h. The optical density
was determined at 450 nm using a microplate reader. Values represent means ± S.E.M. from three different assays. (A) NCI-H1299, (B)
HCT166 p53, and (C) PC-3 cancer cell line. **p< 0.01 compared with control.
394 C. Premakumari et al.(HCT-166 p53) and prostate (PC-3) cancer cell lines by EZ-
cytox cell viability assay kit. To determine the anticancer
activity of bis heterocycles 7–9, the cancer cells were treated
at concentrations from 100 lM for 24 h and measured the cell
viability using the EZ-cytox cell viability kit. As shown in
Fig. 3, the evidence of the anticancer effect of compound 9c
on NCI-H1299, HCT-166 p53 and PC-3 cancer cells can be
seen. The inhibition percentage of compound 9c was 78.60
(NCI-H1299), 58.62 (HCT-166 p53) and 67.91 (PC-3) at
100 lM, respectively (Table 4 and Fig. 3). With compound 9c
(0–100 lM) stimulation for 24 h, cancer cells also decreased in
a dose-dependent manner (Table 5 and Fig. 4). This result sug-
gests that the compound 9c pre-treatment was clearly shown to
modulate the anticancer activity.
4. Conclusion
 A new class of amido-sulfonamido methane linked bis het-
erocycles-bisoxazoles (7), bisthiazoles (8) and bisimidazoles
(9) were prepared from bis(carboxymethyl–sulfonyl)amine
and amino-oxazoles (4), thiazoles (5) and imidazoles (6).
 Bis heterocycles (7–9) were found more active than the
respective mono heterocycles (4–6).
 The compounds having oxazole unit 4 and 7 were found
inactive against both bacteria and fungi.
 Compounds having chloro substituent showed good antimi-
crobial activity.
 The chloro substituted bisimidazole 9c exhibited excellent
antibacterial activity against B. subtilis, P. aeruginosa and
antifungal activity against A. niger, and P. chrysogenum. The compound 9c was the most potent compound on can-
cer cells which may potentiate cancer therapy regimens now
in the development of lung, colon and prostate cancer cell
lines.Acknowledgements
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